The European Association for the Study of Obesity (EASO) released an evidence-based algorithm identifying semaglutide and tirzepatide as leading options for obesity management. Both drugs achieved the greatest weight reduction and improved key complications, including diabetes, cardiovascular disease, and sleep apnea. Lead author Barbara McGowan, MD, of Guy’s and St Thomas’ NHS Trust, emphasized that individualized care should consider comorbidities, treatments, and patient goals. The framework supports, but does not replace, clinical judgment.

Source: Nature Medicine